Lytix Biopharma Balance Sheet Health
Financial Health criteria checks 4/6
Lytix Biopharma has a total shareholder equity of NOK36.8M and total debt of NOK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NOK56.3M and NOK19.5M respectively.
Key information
0%
Debt to equity ratio
NOK 0
Debt
| Interest coverage ratio | n/a |
| Cash | NOK 43.53m |
| Equity | NOK 36.83m |
| Total liabilities | NOK 19.45m |
| Total assets | NOK 56.28m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6BG's short term assets (NOK53.4M) exceed its short term liabilities (NOK17.4M).
Long Term Liabilities: 6BG's short term assets (NOK53.4M) exceed its long term liabilities (NOK2.1M).
Debt to Equity History and Analysis
Debt Level: 6BG is debt free.
Reducing Debt: 6BG has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6BG has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 6BG has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.7% each year